Telomerase reverse transcriptase locus polymorphisms and cancer risk: a field synopsis and meta-analysis - PubMed (original) (raw)
Review
. 2012 Jun 6;104(11):840-54.
doi: 10.1093/jnci/djs222. Epub 2012 Apr 20.
Affiliations
- PMID: 22523397
- PMCID: PMC3611810
- DOI: 10.1093/jnci/djs222
Review
Telomerase reverse transcriptase locus polymorphisms and cancer risk: a field synopsis and meta-analysis
Simone Mocellin et al. J Natl Cancer Inst. 2012.
Abstract
Background: Several recent studies have provided evidence that polymorphisms in the telomerase reverse transcriptase (TERT) gene sequence are associated with cancer development, but a comprehensive synopsis is not available. We conducted a systematic review and meta-analysis of the available molecular epidemiology data regarding the association between TERT locus polymorphisms and predisposition to cancer.
Methods: A systematic review of the English literature was conducted by searching PubMed, Embase, Cancerlit, Google Scholar, and ISI Web of Knowledge databases for studies on associations between TERT locus polymorphisms and cancer risk. Random-effects meta-analysis was performed to pool per-allele odds ratios for TERT locus polymorphisms and risk of cancer, and between-study heterogeneity and potential bias sources (eg, publication and chasing bias) were assessed. Because the TERT locus includes the cleft lip and palate transmembrane 1-like (CLPTM1L) gene, which is in linkage disequilibrium with TERT, CLPTM1L polymorphisms were also analyzed. Cumulative evidence for polymorphisms with statistically significant associations was graded as "strong," "moderate," and "weak" according to the Venice criteria. The joint population attributable risk was calculated for polymorphisms with strong evidence of association.
Results: Eighty-five studies enrolling 490 901 subjects and reporting on 494 allelic contrasts were retrieved. Data were available on 67 TERT locus polymorphisms and 24 tumor types, for a total of 221 unique combinations of polymorphisms and cancer types. Upon meta-analysis, a statistically significant association with the risk of any cancer type was found for 22 polymorphisms. Strong, moderate, and weak cumulative evidence for association with at least one tumor type was demonstrated for 11, 9, and 14 polymorphisms, respectively. For lung cancer, which was the most studied tumor type, the estimated joint population attributable risk for three polymorphisms (TERT rs2736100, intergenic rs4635969, and CLPTM1L rs402710) was 41%. Strong evidence for lack of association was identified for five polymorphisms in three tumor types.
Conclusions: To our knowledge, this is the largest collection of data for associations between TERT locus polymorphisms and cancer risk. Our findings support the hypothesis that genetic variability in this genomic region can modulate cancer susceptibility in humans.
Figures
Figure 1
Flow chart for the estimation of the joint risk of lung adenocarcinoma in the general population attributable to three TERT locus polymorphisms. Top panel. A forest plot depicting the meta-analysis of the studies that contributed to define the association between the minor alleles of three single-nucleotide polymorphisms (SNPs) and the risk of developing lung adenocarcinoma. Open squares represent odds ratios (ORs) of single studies (the width of each square is proportional to the weight of the corresponding study; the horizontal line represents the 95% confidence interval [CI] of the study OR); solid black diamonds represent summary OR for each SNP (the width of each diamond is proportional to the 95% CI of the corresponding summary OR). Bottom left panel. Only SNP showing strong cumulative evidence for association with lung adenocarcinoma were selected. Cumulative evidence was assessed as per the Venice criteria (see text for more details). OR refer to risk alleles (alleles associated with increased cancer risk). Bottom right panel. The joint PAR (population attributable risk) represents the proportion of lung adenocarcinoma cases estimated to be attributable to the three SNPs showing strong cumulative evidence of association; it depends on both the magnitude of the association (OR) and the risk allele frequency in the general population.
Similar articles
- Genetic variants in TERT-CLPTM1L genetic region associated with several types of cancer: a meta-analysis.
Li C, Yin Z, Wu W, Li X, Zhou B. Li C, et al. Gene. 2013 Sep 10;526(2):390-9. doi: 10.1016/j.gene.2013.05.003. Epub 2013 May 23. Gene. 2013. PMID: 23707794 - Association of genetic polymorphisms in TERT-CLPTM1L with lung cancer in a Chinese population.
Liu SG, Ma L, Cen QH, Huang JS, Zhang JX, Zhang JJ. Liu SG, et al. Genet Mol Res. 2015 May 4;14(2):4469-76. doi: 10.4238/2015.May.4.4. Genet Mol Res. 2015. PMID: 25966219 - Genetic polymorphisms of TERT and CLPTM1L and risk of lung cancer--a case-control study in a Chinese population.
Myneni AA, Chang SC, Niu R, Liu L, Ochs-Balcom HM, Li Y, Zhang C, Zhao B, Shi J, Han X, Li J, Su J, Cai L, Yu S, Zhang ZF, Mu L. Myneni AA, et al. Lung Cancer. 2013 May;80(2):131-7. doi: 10.1016/j.lungcan.2013.01.021. Epub 2013 Feb 19. Lung Cancer. 2013. PMID: 23433592 Free PMC article. - The TERT rs2736100 polymorphism and cancer risk: a meta-analysis based on 25 case-control studies.
Zou P, Gu A, Ji G, Zhao L, Zhao P, Lu A. Zou P, et al. BMC Cancer. 2012 Jan 5;12:7. doi: 10.1186/1471-2407-12-7. BMC Cancer. 2012. PMID: 22221621 Free PMC article. Review. - TERT genetic polymorphism rs2736100 was associated with lung cancer: a meta-analysis based on 14,492 subjects.
Wang HM, Zhang XY, Jin B. Wang HM, et al. Genet Test Mol Biomarkers. 2013 Dec;17(12):937-41. doi: 10.1089/gtmb.2013.0322. Genet Test Mol Biomarkers. 2013. PMID: 24283584 Free PMC article. Review.
Cited by
- Telomere length and hTERT genetic variants as potential prognostic markers in multiple myeloma.
Dratwa M, Łacina P, Butrym A, Porzuczek D, Mazur G, Bogunia-Kubik K. Dratwa M, et al. Sci Rep. 2023 Sep 22;13(1):15792. doi: 10.1038/s41598-023-43141-7. Sci Rep. 2023. PMID: 37737335 Free PMC article. - Ethnicity-specific association between TERT rs2736100 (A > C) polymorphism and lung cancer risk: a comprehensive meta-analysis.
Wu X, Huang G, Li W, Chen Y. Wu X, et al. Sci Rep. 2023 Aug 15;13(1):13271. doi: 10.1038/s41598-023-40504-y. Sci Rep. 2023. PMID: 37582820 Free PMC article. - Spotlight on hTERT Complex Regulation in Cutaneous T-Cell Lymphomas.
Ropio J, Prochazkova-Carlotti M, Batista R, Pestana A, Chebly A, Ferrer J, Idrissi Y, Cappellen D, Durães C, Boaventura P, Vinagre J, Azzi-Martin L, Poglio S, Cabeçadas J, Campos MA, Beylot-Barry M, Sobrinho-Simões M, Merlio JP, Soares P, Chevret E. Ropio J, et al. Genes (Basel). 2023 Feb 8;14(2):439. doi: 10.3390/genes14020439. Genes (Basel). 2023. PMID: 36833366 Free PMC article. - Implications of risk conferred by 5p15.33 loci genetic variants; human telomerase reverse transcriptase rs2736098 and rs2736100 in predisposition of bladder cancer.
Anwar I, Pandith AA, Mir H, Manzoor U, Amin I, Baba SM, Godha M, Koul AM, Shah ZA, Mansoor S, Wani MS. Anwar I, et al. Rep Pract Oncol Radiother. 2022 Oct 31;27(5):787-796. doi: 10.5603/RPOR.a2022.0082. eCollection 2022. Rep Pract Oncol Radiother. 2022. PMID: 36523804 Free PMC article. - Identification of rs2736099 as a novel cis-regulatory variation for TERT and implications for tumorigenesis and cell proliferation.
Shi Q, Zhang XX, Shi XQ, Chen Y, Sun C. Shi Q, et al. J Cancer Res Clin Oncol. 2023 Jul;149(8):4515-4522. doi: 10.1007/s00432-022-04372-9. Epub 2022 Sep 21. J Cancer Res Clin Oncol. 2023. PMID: 36131156
References
- Blackburn EH. Switching and signaling at the telomere. Cell. . 2001;106(6):661–673. - PubMed
- Bianchi A, Shore D. How telomerase reaches its end: mechanism of telomerase regulation by the telomeric complex. Mol Cell. . 2008;31(2):153–165. - PubMed
- Blasco MA. Telomeres and human disease: ageing, cancer and beyond. Nat Rev Genet. . 2005;6(8):611–622. - PubMed